| Year of Transplant | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | ||
| Transplants | 88 | 139 | 134 | 168 | 181 | 160 | 183 | 199 | 173 | 208 | |
| Tx with Follow-up Immunosuppression Info | 63 | 109 | 96 | 122 | 141 | 115 | 137 | 148 | 125 | 151 | |
| Corticosteroids | Any in Category | 100.0% | 100.0% | 96.9% | 92.6% | 86.5% | 56.5% | 58.4% | 54.7% | 59.2% | 59.6% |
| Steroids | 100.0% | 100.0% | 96.9% | 92.6% | 86.5% | 56.5% | 58.4% | 54.7% | 59.2% | 59.6% | |
| Cyclosporine | Any in Category | 19.0% | 8.3% | 8.3% | 5.7% | 8.5% | 7.0% | 3.6% | 2.7% | 2.4% | 4.0% |
| Sandimmmune | 0.0% | 0.0% | 2.1% | 0.0% | 0.0% | 0.0% | 0.0% | 1.4% | 0.8% | 0.7% | |
| Neoral | 19.0% | 8.3% | 5.2% | 5.7% | 6.4% | 6.1% | 3.6% | 1.4% | 1.6% | 3.3% | |
| Gengraf | 0.0% | 0.0% | 1.0% | 0.0% | 1.4% | 0.9% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Eon | 0.0% | 0.0% | 0.0% | 0.0% | 0.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Tacrolimus | Any in Category | 96.8% | 96.3% | 95.8% | 98.4% | 95.0% | 84.3% | 85.4% | 97.3% | 97.6% | 95.4% |
| Tacrolimus | 96.8% | 96.3% | 95.8% | 98.4% | 95.0% | 84.3% | 85.4% | 97.3% | 97.6% | 95.4% | |
| Antimetabolites | Any in Category | 93.7% | 93.6% | 81.3% | 73.8% | 63.8% | 60.0% | 60.6% | 64.2% | 60.8% | 62.9% |
| Mycophenolate Mofetil | 81.0% | 91.7% | 76.0% | 70.5% | 63.8% | 59.1% | 54.7% | 56.1% | 52.8% | 52.3% | |
| Mycophenolate Sodium | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 4.7% | 6.4% | 6.6% | |
| Azathioprine | 12.7% | 1.8% | 5.2% | 3.3% | 0.0% | 0.9% | 5.8% | 3.4% | 1.6% | 4.0% | |
| mTOR Inhibitors | Any in Category | 0.0% | 17.4% | 27.1% | 16.4% | 33.3% | 24.3% | 26.3% | 27.7% | 28.8% | 23.8% |
| Sirolimus | 0.0% | 17.4% | 27.1% | 16.4% | 33.3% | 24.3% | 26.3% | 27.7% | 28.8% | 23.8% | |
| Everolimus | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |